Aliases & Classifications for Mucositis

MalaCards integrated aliases for Mucositis:

Name: Mucositis 12 54 44 15 17
Inflammatory Disease of Mucous Membrane 70
Gastrointestinal Mucositis 70

Classifications:



External Ids:

Disease Ontology 12 DOID:0080178
MeSH 44 D052016
UMLS 70 C0333355 C0521585

Summaries for Mucositis

Disease Ontology : 12 A gastrointestinal system disease that is characterized by painful inflammation and ulceration of the mucous membranes lining the digestive tract.

MalaCards based summary : Mucositis, also known as inflammatory disease of mucous membrane, is related to diarrhea and candidiasis, and has symptoms including signs and symptoms, digestive, oral manifestations and catarrh. An important gene associated with Mucositis is CSF3 (Colony Stimulating Factor 3), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include breast, bone marrow and myeloid, and related phenotypes are Increased viability with paclitaxel and growth/size/body region

Wikipedia : 73 Mucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract,... more...

Related Diseases for Mucositis

Diseases related to Mucositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 497)
# Related Disease Score Top Affiliating Genes
1 diarrhea 31.2 IL2 IL1B IL10 CSF3 ABCB1
2 candidiasis 31.0 IL2 IL1B IL10 CSF2
3 graft-versus-host disease 31.0 IL2 IL1B IL10
4 acute graft versus host disease 30.9 IL2 IL10 CSF3
5 exanthem 30.9 VEGFA MTOR IL2 IL1B IL10 CSF3
6 dermatitis 30.8 IL2 IL1B IL10 CSF2
7 gingivitis 30.8 IL2 IL1B IL10 CSF3
8 bacterial infectious disease 30.7 IL1B IL10 CSF3 CSF2
9 acute leukemia 30.7 MTHFR IL2 CSF3 CSF2 ABCB1
10 squamous cell carcinoma 30.7 XRCC1 VEGFA RSPO1 EGF CASP3
11 lichen planus 30.7 IL2 IL1B IL10
12 methotrexate toxicity 30.6 TYMS MTHFR ABCB1
13 aphthous stomatitis 30.6 IL2 IL1B IL10 CSF2
14 leukemia, acute lymphoblastic 30.6 XRCC1 TYMS MTHFR IL2 CSF3 CSF2
15 stomatitis 30.6 TYMS MTOR IL2 IL1B IL10 FGF7
16 chlamydia 30.5 IL1B IL10 CSF2
17 neutropenia 30.5 TYMS IL2 IL1B IL11 IL10 DPYD
18 childhood leukemia 30.4 TYMS MTHFR CSF3 ABCB1
19 hepatic veno-occlusive disease 30.3 VEGFA CSF3 ABCB1
20 aspergillosis 30.2 IL1B IL10 CSF3 CSF2
21 lymphoma, non-hodgkin, familial 30.2 IL2 CSF3 CSF2 CASP3 ABCB1
22 hemorrhagic cystitis 30.1 IL2 IL11 CSF3
23 squamous cell carcinoma, head and neck 30.1 VEGFA MET EGF DPYD CSF2 CASP3
24 crohn's disease 30.0 IL2 IL1B IL10 CSF2
25 myeloma, multiple 30.0 VEGFA MTOR IL2 IL1B IL10 CSF3
26 plasmacytoma 30.0 VEGFA IL2 IL11
27 hematologic cancer 30.0 VEGFA MTOR IL2 IL11 FGF7 CSF3
28 osteogenic sarcoma 30.0 IL11 EGF CASP3 ABCB1
29 gastroenteritis 30.0 IL1B IL10 CSF3 CSF2
30 ulcerative colitis 30.0 IL2 IL1B IL10 ABCB1
31 leptospirosis 30.0 IL2 IL1B IL10
32 osteomyelitis 30.0 IL1B IL10 CSF3
33 plague 30.0 IL2 IL1B IL10
34 human cytomegalovirus infection 30.0 MTOR IL1B CASP3
35 kidney cancer 30.0 VEGFA MTOR MET IL2 EGF CSF2
36 colitis 30.0 IL2 IL1B IL11 IL10 ABCB1
37 adult respiratory distress syndrome 30.0 IL1B IL10 FGF7 CSF3
38 cutaneous leishmaniasis 29.9 IL2 IL1B IL10
39 end stage renal disease 29.9 VEGFA MTHFR IL1B IL10
40 toxic shock syndrome 29.9 IL2 IL1B IL10
41 lung cancer susceptibility 3 29.9 VEGFA MET EGF CASP3 ABCB1
42 acquired immunodeficiency syndrome 29.9 IL2 IL1B IL10 CSF2
43 lymphadenitis 29.9 IL1B IL10 CASP3
44 allergic disease 29.9 IL2 IL1B IL10 CSF2
45 gingival overgrowth 29.9 IL2 FGF7 EGF ABCB1
46 rubella 29.9 IL2 IL1B IL10
47 childhood acute lymphocytic leukemia 29.9 XRCC1 VEGFA TYMS MTHFR ABCB1
48 fungal infectious disease 29.8 IL2 IL1B IL10 CSF3 CSF2
49 chronic mucocutaneous candidiasis 29.8 IL2 IL1B IL10 CSF3 CSF2
50 severe combined immunodeficiency 29.8 VEGFA IL2 IL10 CSF3 CSF2

Graphical network of the top 20 diseases related to Mucositis:



Diseases related to Mucositis

Symptoms & Phenotypes for Mucositis

UMLS symptoms related to Mucositis:


signs and symptoms, digestive; oral manifestations; catarrh

GenomeRNAi Phenotypes related to Mucositis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with paclitaxel GR00179-A-1 8.32 CASP3

MGI Mouse Phenotypes related to Mucositis:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.4 ABCB1 CASP3 CSF2 EGF FGF7 IL10
2 behavior/neurological MP:0005386 10.37 ABCB1 CASP3 CSF2 DPYD FGF7 IL10
3 immune system MP:0005387 10.35 ABCB1 CASP3 CSF2 CSF3 DPYD EGF
4 homeostasis/metabolism MP:0005376 10.34 ABCB1 CASP3 CSF2 FGF7 IL10 IL1B
5 hematopoietic system MP:0005397 10.32 ABCB1 CASP3 CSF2 CSF3 DPYD FGF7
6 endocrine/exocrine gland MP:0005379 10.24 ABCB1 CASP3 CSF2 EGF IL10 IL2
7 nervous system MP:0003631 10.22 ABCB1 CASP3 CSF2 FGF20 FGF7 IL10
8 digestive/alimentary MP:0005381 10.2 ABCB1 CASP3 DPYD EGF IL10 IL2
9 integument MP:0010771 10.2 CASP3 CSF2 CSF3 EGF FGF20 FGF7
10 reproductive system MP:0005389 10 ABCB1 CASP3 CSF2 DPYD EGF FGF7
11 neoplasm MP:0002006 9.98 CSF2 IL10 IL1B IL2 MET VEGFA
12 no phenotypic analysis MP:0003012 9.97 ABCB1 CASP3 IL10 IL2 MET MTHFR
13 renal/urinary system MP:0005367 9.92 CASP3 CSF2 CSF3 FGF7 MET MTOR
14 respiratory system MP:0005388 9.76 CASP3 CSF2 IL10 IL2 MET MTOR
15 skeleton MP:0005390 9.65 CASP3 CSF2 FGF7 IL10 IL1B MTHFR
16 vision/eye MP:0005391 9.32 CASP3 EGF FGF7 IL10 IL2 MET

Drugs & Therapeutics for Mucositis

Drugs for Mucositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 593)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
2
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
3
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
4
Prilocaine Approved Phase 4 721-50-6 4906
5
Acetaminophen Approved Phase 4 103-90-2 1983
6
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
7
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
8
Methylene blue Approved, Investigational Phase 4 61-73-4
9
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
10
Budesonide Approved Phase 4 51333-22-3 63006 5281004
11
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
12
Hexetidine Approved, Investigational Phase 4 141-94-6
13
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
14
Capsaicin Approved Phase 4 404-86-4 1548943
15
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
16
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
17
Alosetron Approved, Withdrawn Phase 4 122852-42-0 2099
18
Rofecoxib Approved, Investigational, Withdrawn Phase 4 162011-90-7 5090
19
Esomeprazole Approved, Investigational Phase 4 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
20
Ofloxacin Approved Phase 4 82419-36-1 4583
21
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
22
Metronidazole Approved Phase 4 443-48-1 4173
23
Copper Approved, Investigational Phase 4 7440-50-8 27099
24
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
25
Vedolizumab Approved Phase 4 943609-66-3
26
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
27
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
28
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
29
Morphine Approved, Investigational Phase 4 57-27-2 5288826
30
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
31
tannic acid Approved Phase 4 1401-55-4
32
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
33
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
34
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
35
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
36
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
37
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
38
Amifostine Approved, Investigational Phase 4 20537-88-6 2141
39
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
40
Promethazine Approved, Investigational Phase 4 60-87-7 4927
41
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
42
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
43
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
44
Povidone Approved Phase 4 9003-39-8 131751496
45
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
46
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
47
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
48
Ibuprofen Approved Phase 4 15687-27-1 3672
49
Sodium citrate Approved, Investigational Phase 4 68-04-2
50
Simethicone Approved Phase 4 8050-81-5

Interventional clinical trials:

(show top 50) (show all 1037)
# Name Status NCT ID Phase Drugs
1 Personalized Peroral Endoscopic Myotomy for Achalasia Unknown status NCT01570621 Phase 4
2 Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer Unknown status NCT01876407 Phase 4
3 A Prospective, Randomized Controlled Open Research About the Impact of Nutritional Support on the Radiation Tolerance and Clinical Outcomes for Local Advanced Nasopharyngeal Carcinoma Patients Unknown status NCT02948699 Phase 4
4 Efficacy of Two Different Oral Hygiene Regimens on the Incidence and Severity of Oral Mucositis in Patients Receiving Hematopoietic Stem Cell Transplantation - A Randomized Controlled Trial Unknown status NCT02662374 Phase 4 .02% Chlorohexidine Gluconate;3% Sodium Bicarbonate;Nystatin 10000U/ml;Supersaturated Calcium Phosphate
5 A Randomized Study on the Effects of Lactobacillus Brevis CD2 in the Prevention of Radio and Chemotherapy Induced Oral Mucositis in Head and Neck Cancer Patients. Unknown status NCT01707641 Phase 4
6 Analysis of the Impact of Helicobacter Pylori Infection and Eradication on Salivary Microbiome in Adults by 16S Pyrosequencing Unknown status NCT03730766 Phase 4 Esomeprazole;Amoxicillin;Bismuth Potassium Citrate
7 Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies Unknown status NCT02951559 Phase 4
8 The Effect of Lidocaine - Prilocaine Cream (EMLA) Versus Mepivacaine Infiltration on Pain Relief During And After Mediolateral Episiotomies: A Randomized Clinical Trial Unknown status NCT03264586 Phase 4 Lidocaine-prilocaine cream;mepivacaine infiltration group
9 Atomization of Fentanyl: A Randomized Comparison Study of Intranasal Versus Intravenous Fentanyl for Pre-hospital Pain Management Unknown status NCT00882960 Phase 4 intravenous fentanyl;intra-nasal fentanyl
10 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
11 Helicobacter Pylori Eradication Therapy on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection of Gastric Neoplastic Lesions: a Multicenter, Randomized, Double Blind, and Placebo Controlled Trial Unknown status NCT00926809 Phase 4 Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin;Lansoprazole (proton pump inhibitor), placebo
12 Italian Multicenter Prospective Randomized Trial to Compare Additive Hemostatic Efficacy of EndoClot System to Prevent Bleeding After Endoscopic Mucosal Resection or Endoscopic Submucosal Dissection of Lesions in the Gastrointestinal Tract Unknown status NCT02688699 Phase 4
13 Protective Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Unknown status NCT02175186 Phase 4 ALBIS;Placebo
14 A Study to Investigate the Gastrointestinal Safety of OTC Analgesics in Healthy Volunteers by Endoscopic Examination Completed NCT01822665 Phase 4 Ibuprofen;Paracetamol
15 Gastrointestinal Mucosal Findings in Patients Receiving Mycophenolic Acid (MPA) as Demonstrated by Small Bowel Capsule Endoscopy (SBCE) Completed NCT00652834 Phase 4 myfortic
16 Clinical and Microbiological Evaluation of the Effect of Probiotic Lactobacillus Reuteri Prodentis in the Treatment of Mucositis and Periimplantitis Completed NCT03047291 Phase 4 Probiotic
17 A Comparison Among Three Single-incision Devices for the Treatment of Female Urinary Genuine Stress Incontinence: a Randomized Controlled Study. Completed NCT00751088 Phase 4
18 Prospective Comparison of NBI and i-Scan in Real-time Histological Prediction of Diminutive Colonic Polyps Completed NCT01133041 Phase 4
19 Prehospital Analgesia With Intra-Nasal Ketamine Completed NCT02753114 Phase 4 Ketamine;Normal Saline
20 A Comparison of Intranasal Midazolam and Nitrous Oxide (N2O) Minimal Sedation for Minor Procedures in a Pediatric Emergency Department Completed NCT03085563 Phase 4 Nitrous Oxide;Midazolam
21 Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis: A Randomized, Double Blind Placebo Controlled Trial Completed NCT01482091 Phase 4 Fentanyl Citrate;Normal Saline
22 A Prospective Audit of Tolerability, Mucosal Cleansing Efficacy and Mucosal Abnormalities Associated With Standard Orally Administered Colon Cleansing Preparations for Colonoscopy Completed NCT00750763 Phase 4 Colonlytely;Picolax/Picoprep;Fleet
23 Effect of Enteral Immunonutrition During Chemoradiotherapy in Patients With Head and Neck Cancer or Esophageal Cancer Completed NCT00333099 Phase 4
24 Impact of Oral Hygiene Gels on Peri-implant Mucositis Completed NCT03243591 Phase 4
25 A Ramdomized Double Blined Placebo Controlled Oral Zinc Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Stem Cell Support Completed NCT00449592 Phase 4 Zinc;Placebo
26 Evaluation of the Efficacy of a Hexetidine- and Chlorobutanol-based Mouthwash in the Symptomatic Treatment of Oral Lesions Due to Removable Prostheses: a Prospective, Randomized, Triple-blind Controlled Clinical Trial Completed NCT01115049 Phase 4 chlorobutanol, hexetidine;Chlorhexidine
27 A Randomized, Double-blind Study to Evaluate the Efficacy of MuGard Mucoadhesive Oral Wound Rinse for the Amelioration of Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck Completed NCT01283906 Phase 4
28 The Use of Erythritol Powder and Locally Derived Metronidazole for the Non-surgical Treatment of Peri-implant Mucositis and Peri-implantitis. Completed NCT02023853 Phase 4 metronidazole gel
29 Physiological Changes in Nasal Patency in Response to Changes in Posture, Temperature, Humidity and Nasal Patency Measured by Acoustic Rhinometry Completed NCT00147888 Phase 4
30 Premedication With Simethicone and N-acetylcysteine in Improving Mucosal Visibility During Upper Endoscopy - a Prospective Double-blinded Randomized Controlled Trial Completed NCT02357303 Phase 4 Simethicone;Acetylcysteine
31 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
32 Local Administration of Morphine: An Evaluation of the Analgesic Effect at Stomatitis in Children Completed NCT00357942 Phase 4 morphine solution for injection;Placebo;morphine mouthwash;Placebo
33 Recto Colonic Endoscopic Mucosal Resection and Polypectomy Under Clopidogrel: the "MEDOC"Study. Completed NCT01807169 Phase 4
34 Efficacy of High Dose of Amoxicillin And Metronidazole Plus Bismuth For Helicobacter Pylori Treatment In Naive Patients : A Randomized Clinical Trial Completed NCT03557437 Phase 4 Esomeprazole;Amoxicillin, Metronidazole;Bismuth Potassium Citrate
35 Antibiotic Susceptibility-based Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy: a Prospective Clinical Trial Completed NCT03708848 Phase 4 Esomeprazole;Bismuth Potassium Citrate;Clarithromycin;Metronidazole;Levofloxacin;Tetracycline
36 Intranasal Fentanyl Versus Intravenous Morphine in the Emergency Department Treatment of Severe Painful Sickle Cell Crises in Children Completed NCT03682211 Phase 4 Fentanyl Citrate;Morphine sulphate
37 Efficacy of Antibiotic Susceptibility-based Tailored Versus Empiric Therapy for Helicobacter Pylori First-line Treatment:a Randomized Clinical Trial Completed NCT02935010 Phase 4 Esomeprazole;Bismuth Potassium Citrate;Amoxicillin;Clarithromycin;Metronidazole;Levofloxacin
38 Efficacy of the Dental Vibe Unit for Use of Reduction or Elimination of Pain During Dental Anesthetic Injection Completed NCT02414620 Phase 4
39 Efficacy of High Dose of Dual Therapy Plus Bismuth for Helicobacter Pylori Treatment:a Randomized Clinical Trial Completed NCT03405584 Phase 4 Esomeprazole;Amoxicillin;Bismuth Potassium Citrate
40 A Randomized Prospective Study of Endoscopy Bipolar Eletrocoagulation and Argon Plasma Coagulation of Chronic Rectal Bleeding From Radiation Telangiectasias Completed NCT00725244 Phase 4
41 Efficacy of Tailored for Helicobacter Pylori Rescue Treatment Based on Antimicrobial-susceptibility Testing Completed NCT03413020 Phase 4 esomeprazole;bismuth Potassium Citrate;amoxicillin;clarithromycin;metronidazole;levofloxacin
42 The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (the ICE Study) Completed NCT01181765 Phase 4
43 Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia: A Randomized Prospective Comparison of Snares and Injectate in the Resection of Large Sessile Colonic Polyps Completed NCT01471756 Phase 4
44 A Placebo Controlled, Double-Blind, Randomised Study to Assess Efficacy of Sublingual Immunotherapy in Patients With Grass Pollen Allergy Through Assessment of Its Immunological Effects on the Mucosal Tissue of the Nose. Completed NCT00150514 Phase 4 Oralgen
45 A Randomize, Placebo-controlled, Crossover Study to Measure the Effect of Alosetron on Mucosal Blood Flow in Female Healthy Volunteers and Diarrhea-predominant IBS Subjects Completed NCT00370032 Phase 4 alosetron
46 Effect of Analgesics on the Irreversible Inactivation of Cyclooxygenase-1 Activity by Low Dose Aspirin and Endoscopic Evaluation of the Gastric Mucosal Effect Completed NCT00261586 Phase 4 aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxib
47 Unraveling the Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls by Measuring Mucosal Potentials in the Nose. Completed NCT01862523 Phase 4
48 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
49 The Human Mucosal Immune Responses to Influenza Virus: A Systems Biology Approach. Innate Immune Responses to Influenza Virus in Single Human Nasal Epithelial Cells Completed NCT03023553 Phase 4
50 A Randomized, Double-blind, Comparative, Effectiveness and Safety Study of Eleview vs. Hetastarch in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to or Larger Than 11mm Completed NCT03350217 Phase 4 Eleview;Hetastarch

Search NIH Clinical Center for Mucositis

Cochrane evidence based reviews: mucositis

Genetic Tests for Mucositis

Anatomical Context for Mucositis

MalaCards organs/tissues related to Mucositis:

40
Breast, Bone Marrow, Myeloid, Colon, Skin, Bone, Tongue

Publications for Mucositis

Articles related to Mucositis:

(show top 50) (show all 10174)
# Title Authors PMID Year
1
The use of GLP-2 and related growth factors in intestinal diseases. 61 54
20336592 2010
2
Keratinocyte growth factor. 54 61
19456212 2009
3
Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. 61 54
18829546 2008
4
Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. 54 61
18197435 2008
5
Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. 54 61
18560408 2008
6
Cytokines following SCT: indications and controversies. 61 54
18545239 2008
7
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. 61 54
18299612 2008
8
The effect of palifermin on chemotherapyand radiation therapy-induced mucositis: a review of the current literature. 61 54
18632516 2007
9
DPYD*2A mutation: the most common mutation associated with DPD deficiency. 61 54
17165084 2007
10
Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant. 54 61
17728847 2007
11
Head and neck radiation and mucositis. 61 54
18660721 2007
12
Interventions for treating oral mucositis for patients with cancer receiving treatment. 54 61
17443514 2007
13
The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901. 61 54
17293228 2007
14
Cancer treatment-induced oral mucositis. 54 61
17465250 2007
15
Palifermin: a keratinocyte growth factor that reduces oral mucositis after stem cell transplant for haematological malignancies. 54 61
17059384 2006
16
A protective role for keratinocyte growth factor in a murine model of chemotherapy and radiotherapy-induced mucositis. 61 54
16904525 2006
17
[Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients]. 61 54
16965690 2006
18
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. 54 61
16912178 2006
19
Emerging approaches for prophylaxis and management of oropharyngeal mucositis in cancer therapy. 61 54
16634706 2006
20
Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. 61 54
16803675 2006
21
Effect of granulocyte macrophage-colony stimulating factor (GM-CSF) on 5-FU-induced ulcerative mucositis in hamster buccal pouches. 54 61
16414253 2006
22
Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy. 61 54
16537186 2006
23
R-Spondin proteins: a novel link to beta-catenin activation. 61 54
16357527 2006
24
The molecular immunology of mucositis: implications for evidence-based research in alternative and complementary palliative treatments. 54 61
16322806 2005
25
Mucosal protection by cytokines. 54 61
16232381 2005
26
Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. 61 54
15683818 2005
27
Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy: a multicenter open randomized phase III study. 61 54
16110136 2005
28
Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. 54 61
15623608 2004
29
Interventions for treating oral mucositis for patients with cancer receiving treatment. 61 54
15106165 2004
30
Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. 61 54
12649101 2003
31
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. 54 61
12697866 2003
32
Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature. 54 61
12759532 2003
33
Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. 61 54
12243825 2002
34
The effects of keratinocyte growth factor in preclinical models of mucositis. 54 61
12139710 2002
35
Are Central Eastern European countries involved in clinical trials of supportive care? 61 54
12029429 2002
36
A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. 54 61
11919725 2002
37
Biological actions and therapeutic potential of the glucagon-like peptides. 54 61
11832466 2002
38
Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. 54 61
11597377 2001
39
Oral pseudomembranous candidiasis, herpes simplex virus-1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwash. 54 61
11545238 2001
40
Genomics and drug discovery. 54 61
11511852 2001
41
Comment on: Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. 61 54
11503611 2001
42
Repifermin. Human Genome Sciences/GlaxoSmithKline. 54 61
15995938 2001
43
Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. 61 54
11313683 2001
44
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. 54 61
11212269 2001
45
Prevention and management of mucositis in patients with cancer. 54 61
11053801 2000
46
Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. 54 61
10899677 2000
47
Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. 61 54
10701730 2000
48
Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. 54 61
10578158 1999
49
Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. 54 61
10473079 1999
50
The biological basis for the attenuation of mucositis: the example of interleukin-11. 54 61
10360368 1999

Variations for Mucositis

Expression for Mucositis

Search GEO for disease gene expression data for Mucositis.

Pathways for Mucositis

Pathways related to Mucositis according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 VEGFA MTOR MET IL2 IL1B IL11
2
Show member pathways
13.71 TGFB3 MTOR MET IL2 IL1B IL11
3
Show member pathways
13.68 VEGFA TGFB3 MTOR MET IL2 IL1B
4
Show member pathways
13.54 VEGFA TGFB3 MTOR MET IL2 IL1B
5
Show member pathways
13.3 VEGFA TGFB3 MET IL2 FGF7 FGF20
6
Show member pathways
13.21 VEGFA MET IL2 IL1B IL11 IL10
7
Show member pathways
13.12 TGFB3 MTOR MET IL2 IL1B IL11
8
Show member pathways
13.1 TGFB3 MTOR MET IL2 FGF7 FGF20
9
Show member pathways
13.1 TGFB3 MET IL2 IL1B IL11 IL10
10
Show member pathways
13.09 TGFB3 MTOR MET IL2 FGF7 FGF20
11
Show member pathways
12.97 VEGFA MTOR MET IL2 FGF7 FGF20
12
Show member pathways
12.91 VEGFA TGFB3 MTOR EGF CSF2 CASP3
13
Show member pathways
12.89 VEGFA IL2 IL1B IL10 CASP3 ABCB1
14
Show member pathways
12.81 TGFB3 MTOR MET FGF7 FGF20 EGF
15 12.78 VEGFA TGFB3 MTOR MET IL2 FGF7
16
Show member pathways
12.76 VEGFA MET FGF7 FGF20